Table 3.
Population allele frequency and statistical power
| Phenotype | Locus | SNP | OR | Case MAF | Cases (n) | Control MAF | Controls (n) | Population MAFa | Power (%)c |
|---|---|---|---|---|---|---|---|---|---|
| WNND | TFCP2L1 | rs11122852 | 3.57 | 0.0328 | 609 | 0.0094 | 954 | 0.0079 | 99 |
| rs7563166 | 3.58 | 0.0222 | 609 | 0.0063 | 954 | 0.0079 | 96 | ||
| rs6756142 | 3.91 | 0.0222 | 609 | 0.0058 | 954 | 0.0079 | 97 | ||
| Encephalitis | CACNA1H | rs78879053 | 37.88 | 0.0133 | 225 | 0.0004 | 954 | 0.003b | 96 |
| CACNA1H | rs113802594 | 5.40 | 0.0133 | 225 | 0.0025 | 954 | 0.005b | 84 | |
| OFCC1 | rs72653717 | NA | 0.0067 | 225 | 0.0000 | 954 | 0b | NA | |
| AFP | TFCP2L1 | rs11122852 | 4.94 | 0.0449 | 267 | 0.0094 | 954 | 0.0079 | 100 |
| rs7563166 | 4.88 | 0.0300 | 267 | 0.0063 | 954 | 0.0079 | 99 | ||
| rs6756142 | 4.30 | 0.0243 | 267 | 0.0058 | 954 | 0.0079 | 95 |
CEU and GBI populations, 1000 Genomes Phase 3 release
Shown are MAF for European populations as MAF was 0 in CEU and GBI
Based on alpha of 0.05, case prevalence of 0.00714 (WNND in 1/140 of exposed), the respective odds ratios, risk allele frequencies, and sample population numbers for each variant.